Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum) under certain conditions (e.g., when Ki-67 is at a high level [upper G2 range], in rapidly progressive disease and/or after failure of other therapies, or if somatostatin receptor imaging is negative). An ENETS Consensus Conference was held in Antibes (2015) to elaborate guidelines on the standards of care of different diagnostic procedures and therapeutic interventions in NENs. This article provides guidance on chemotherapy including therapeutic indications, dosing schedules, adverse events (including prevention and management), drug interactions, and evaluation of treatment effect for the chemotherapy agents most commonly used in NENs (streptozocin, dacarbazine, fluoropyrimidines, platinum compounds, etoposide, and irinotecan).

1.
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al; Vienna Consensus Conference participants: ENETS Consensus Guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 2016;103:186-194.
2.
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al; Vienna Consensus Conference: ENETS Consensus Guidelines Update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172-185.
3.
Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189-1194.
4.
Eriksson B, Öberg K: An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-208.
5.
Moertel CG, Lefkopoulo M, Lipsity S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
6.
Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K: Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883-1890.
7.
Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, et al: Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal 2012;2012:170496.
8.
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.
9.
Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617-4622.
10.
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-275.
11.
Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G, Rodriguez T: A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP 2013;14:498-501.
12.
Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, et al: Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013;71:663-670.
13.
Altimari A, Badrinath K, Reisel H, Prinz RA: DTIC therapy in patients with malignant intraabdominal neuroendocrine tumors. Surgery 1987;102:1009-1017.
14.
Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139-1143.
15.
Mueller D, Krug S, Majumder M, Rinke A, Gress TM: Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. BMC Cancer 2016;16:645.
16.
Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-642.
17.
Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, et al: Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015;22:289-298.
18.
Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, et al: FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012;19:751-757.
19.
Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theo-Anton N, et al: MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016;23:625-633.
20.
Schmitt AM, Pavel M, Rudolph T, Dawson H, Blank A, Komminoth P, et al: Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. Neuroendocrinology 2014;100:35-44.
21.
Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-345.
22.
Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
23.
Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, et al: Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355.
24.
Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al: Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 2010;40:313-318.
25.
Di Meglio G, Massacesi C, Radice D, Boselli S, Pelosi G, Squadroni M, et al: Carboplatin with etoposide in patients with extrapulmonary “aggressive” neuroendocrine carcinoma. J Clin Oncol 2010;28(suppl):e13072.
26.
Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, et al: A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:1033-1038.
27.
Lu Z, Li J, Lu M, Zhang XT, Li J, Zhou J, et al: Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas. Med Oncol 2013;30:1-5.
28.
Nakano K, Takahashi S, Yuasa T, Nishimura N, Mishima Y, Sakajiri S, et al: Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol 2012;42:697-703.
29.
Perry MC (ed): The Chemotherapy Source Book, ed 5. Philadelphia, Lippincot Williams & Wilkinson, 2016.
30.
Speth PA, van Hoesel QG, Haanen C: Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15-31.
31.
Weiss RB: Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982;66:427-438.
32.
Al-Badr AA, Alodhaib MM: Dacarbazine. Profiles Drug Subst Excip Relat Methodol 2016;41:323-377.
33.
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
34.
Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, et al: Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology 2015;101:274-288.
35.
Schilsky RL: Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park) 1998;12(10 suppl 7):13-18.
36.
Diasio RB, Johnson MR: The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000;61:199-203.
37.
Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104.
38.
Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, et al: Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001;12:1301-1306.
39.
Mercier C, Ciccolini J: Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 2006;6:288-296.
40.
Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422.
41.
Alberts DS: Clinical pharmacology of carboplatin. Semin Oncol 1990;17(4 suppl 7):6-8.
42.
Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-235.
43.
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-1218.
44.
Carney DN: The pharmacology of intravenous and oral etoposide. Cancer 1991;67(1 suppl):299-302.
45.
Joel S: The clinical pharmacology of etoposide: an update. Cancer Treat Rev 1996;22:179-221.
46.
Stewart CF: Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994;34(suppl):S76-S83.
47.
Garcia-Carbonero R, Supko JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-661.
48.
Fujita K, Sparreboom A: Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 2010;5:209-217.
49.
Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al: Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267-3285.
50.
Jain D: Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000;7:53-62.
51.
Macdonald JS: Toxicity of 5-fluorouracil. Oncology (Williston Park) 1999;13(7 suppl 3):33-34.
52.
Mikhail SE, Sun JF, Marshall JL: Safety of capecitabine: a review. Expert Opin Drug Saf 2010;9:831-841.
53.
Hartmann JT, Lipp HP: Toxicity of platinum compounds. Expert Opin Pharmacother 2003;4:889-901.
54.
Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmès P: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994;35:1-9.
55.
Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al: Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer 2012;11:93-100.
56.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-4198.
57.
Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, et al: Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 2016;34:381-386.
58.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015;33:3199-3212.
59.
Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, et al: Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol 2015;33:2212-2220.
60.
Perez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group: Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol 2012;23(suppl 7):vii167-vii173.
61.
Common Terminology Criteria for Adverse Events (CTCAE) (v4.03; June 14, 2010). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
62.
Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. US Food and Drug Administration (FDA). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm.
63.
Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, et al: Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997;25:270-273.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.